Posted by Michael Wonder on 22 Nov 2021
Obseva announces U.S. FDA acceptance of new drug application for linzagolix
22 November 2021 - FDA accepts new drug application for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids.
The FDA set a target action date of 13 September 2022 for this new drug application under the Prescription Drug User Fee Act.
